News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
The index options put/call ratio reported 1.01.
CoinWorld US stock market data: The index options Put/Call ratio is 1.01, with put option trading volume higher than call option volume on the day. Compared with the same-caliber snapshot 24 hours earlier, it rose by 0.02; compared with the same-caliber snapshot 7 days earlier, it fell by 0.05.
KuCoin Futures will list perpetual contracts for multiple stock indices.
KuCoin has announced that it will list multiple stock index perpetual contracts on October 21, 2026, according to BiJie.com.
Bank Indonesia Governor: As of October 20, the hedging cost incentive measures have effectively attracted $9.9 billion in foreign investment.
According to CoinWorld news, the Governor of Bank Indonesia stated that as of October 20, Indonesia's hedging cost incentive measures had effectively attracted 9.9 billion US dollars in foreign investment.
Indonesia's benchmark stock index narrowed its decline ahead of the central bank's rate decision, down 0.3% at the latest.
CoinWorld news: Indonesia's benchmark stock index narrowed its decline ahead of Bank Indonesia's interest rate decision, and was last down 0.3%.
Ukraine says Russian attack on Kyiv kills 2 and wounds 2
According to CoinWorld news, on October 21 local time, Kyiv Mayor Klitschko reported that Kyiv was attacked by Russian forces that morning. The attack occurred in the Sviatoshyn district and has resulted in 2 deaths and 2 injuries; all the injured have been taken to hospital for treatment. Russia has not yet responded to this.
Bank Indonesia Governor: Maintaining the 2026 growth target at 4.9%-5.7%.
Bank Indonesia's governor stated that the 2026 economic growth target is maintained between 4.9% and 5.7%.
A whale bought 814,700 ZEC from Binance, worth about $1.03 million.
Bjie.com data: OnchainLens reports that a whale purchased 814.7 ZEC from Binance, worth approximately $1.03 million. This withdrawal was immediately followed by a small test transfer of 0.4995 ZEC, worth about $629, completed just 24 minutes ago.
Anthropic CEO's rare long-form defense: AI is moving so fast that it must be slowed down, yet the company still needs to stay at the forefront.
Coin World news: Anthropic CEO Dario Amodei rarely published a long post on social media defending the company, saying it must stay ahead in AI research and development, even though the rapid development of AI technology may require slowing down. He pointed out that Anthropic recently submitted a draft AI safety bill to U.S. lawmakers, which was questioned. The draft sets a high threshold for the government to urgently halt dangerous models; the risk must involve scenarios such as biological weapons, cyberattacks, or AI going out of control, and may cause more than 50 deaths or serious injuries, or more than $1 billion in losses. Amodei acknowledged that the company has made mistakes, but insisted that competing for the most advanced AI capabilities does not violate its safety mission. The company plans to propose relevant policy solutions by January 15, 2027, or explain why it did not propose them.